Table 2.
KEGG pathway analysis for the differentially expressed proteins
| Term | Count | % | P Value | Benjamini | |
|---|---|---|---|---|---|
|
PSP vs. HC |
Axon guidance | 12 | 6.6 | 8.E-06 | 1.30E-03 |
| Lysosome | 8 | 4.4 | 9.E-04 | 6.80E-02 | |
| Metabolic pathways | 31 | 16.9 | 2.E-03 | 9.30E-02 | |
| Cell adhesion molecules | 8 | 4.4 | 2.E-03 | 9.30E-02 | |
| Glycosphingolipid biosynthesis - lacto and neolacto series | 4 | 2.2 | 4.E-03 | 1.20E-01 | |
| Other types of O-glycan biosynthesis | 4 | 2.2 | 2.E-02 | 4.40E-01 | |
| N-Glycan biosynthesis | 4 | 2.2 | 2.E-02 | 4.40E-01 | |
| Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 3 | 1.6 | 2.E-02 | 4.40E-01 | |
| Renin-angiotensin system | 3 | 1.6 | 3.E-02 | 5.00E-01 | |
| Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 3 | 1.6 | 3.E-02 | 5.00E-01 | |
| Amphetamine addiction | 4 | 2.2 | 5.E-02 | 6.70E-01 | |
| Various types of N-glycan biosynthesis | 3 | 1.6 | 8.E-02 | 1.00E + 00 | |
| Type I diabetes mellitus | 3 | 1.6 | 9.E-02 | 1.00E + 00 | |
|
PSP vs. PD |
Cell adhesion molecules | 8 | 5.4 | 4.E-04 | 5.60E-02 |
| Cholesterol metabolism | 5 | 3.4 | 1.E-03 | 6.60E-02 | |
| Glycosphingolipid biosynthesis - lacto and neolacto series | 4 | 2.7 | 2.E-03 | 7.20E-02 | |
| Glycosaminoglycan biosynthesis - keratan sulfate | 3 | 2 | 7.E-03 | 2.10E-01 | |
| Other types of O-glycan biosynthesis | 4 | 2.7 | 8.E-03 | 2.10E-01 | |
| Metabolic pathways | 23 | 15.5 | 1.E-02 | 2.30E-01 | |
| Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 3 | 2 | 1.E-02 | 2.50E-01 | |
| Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 3 | 2 | 2.E-02 | 3.10E-01 | |
| Lysosome | 5 | 3.4 | 3.E-02 | 4.20E-01 | |
| Various types of N-glycan biosynthesis | 3 | 2 | 5.E-02 | 6.00E-01 | |
| Prostate cancer | 4 | 2.7 | 5.E-02 | 6.40E-01 | |
| N-Glycan biosynthesis | 3 | 2 | 7.E-02 | 7.80E-01 | |
| Sphingolipid metabolism | 3 | 2 | 8.E-02 | 8.00E-01 | |
|
PSP vs. PD + HC |
Cell adhesion molecules | 16 | 6.6 | 6.70E-09 | 1.20E-06 |
| Axon guidance | 14 | 5.8 | 2.10E-06 | 1.90E-04 | |
| Cholesterol metabolism | 7 | 2.9 | 8.80E-05 | 5.30E-03 | |
| Lysosome | 9 | 3.7 | 6.50E-04 | 2.90E-02 | |
| Various types of N-glycan biosynthesis | 5 | 2.1 | 3.10E-03 | 1.10E-01 | |
| Other types of O-glycan biosynthesis | 5 | 2.1 | 4.70E-03 | 1.30E-01 | |
| Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 4 | 1.7 | 4.80E-03 | 1.30E-01 | |
| Glycosphingolipid biosynthesis - lacto and neolacto series | 4 | 1.7 | 6.80E-03 | 1.50E-01 | |
| N-Glycan biosynthesis | 5 | 2.1 | 7.20E-03 | 1.50E-01 | |
| Metabolic pathways | 33 | 13.7 | 1.90E-02 | 3.50E-01 | |
| Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 3 | 1.7 | 3.70E-02 | 6.10E-01 | |
| Renin-angiotensin system | 3 | 1.2 | 4.30E-02 | 6.60E-01 | |
| Amphetamine addiction | 4 | 1.7 | 7.90E-02 | 1.00E + 00 | |
| Mucin type O-glycan biosynthesis | 3 | 1.2 | 9.60E-02 | 1.00E + 00 |